Meduri G U, Cook T R, Turner R E, Cohen M, Leeper K V
Division of Pulmonary and Critical Care Medicine, University of Tennessee, Memphis 38163, USA.
Chest. 1996 Sep;110(3):767-74. doi: 10.1378/chest.110.3.767.
In asthmatic patients with acute respiratory failure (ARF), placing an endotracheal tube is associated with a high rate of complications and results in increased airway resistance. In acute asthma, mask-continuous positive airway pressure (CPAP) decreases airway resistance and the work of breathing (WOB), but does not improve gas exchange. In COPD with ARF, adding intermittent positive pressure ventilation to mask-CPAP results in an additional improvement in WOB and is highly effective in correcting gas exchange abnormalities. In our medical ICU, noninvasive positive pressure ventilation (NPPV) is used as first-line interventional therapy in eligible patients with hypercapnic ARF. We report our experience with NPPV in 17 episodes of asthma and ARF over a 3-year period.
A face mask was secured with head straps, avoiding a tight fit, and connected to a ventilator (PB-7200). Initial ventilatory settings included CPAP at 4 +/- 2 cm H2O to offset intrinsic positive end-expiratory pressure and pressure support ventilation (PSV) at 14 +/- 5 cm H2O aiming at a respiratory rate less than 25 breaths/min and an exhaled tidal volume of 7 mL/kg or more. PSV was then adjusted following arterial blood gas results.
Mean age was 35.4 +/- 11.3 years; 10 patients were female. The mean (+/- SE) for different physiologic values are reported at initiation, less than 2 h, 2 to 6 h, and 12 to 24 h into NPPV. pH was 7.25 +/- 0.01, 7.32 +/- 0.02 (p = 0.0012), 7.36 +/- 0.02 (p < 0.0001), and 7.38 +/- 0.02; PaCO2 was 65 +/- 2, 52 +/- 3(p = 0.002), 45 +/- 3(p < 0.0001), and 45 +/- 4; PaO2 fraction of inspired oxygen was 315 +/- 41, 403 +/- 47, 367 +/- 47, and 472 +/- 67 (p = 0.06); and respiratory rate was: 29.1 +/- 1, 22 +/- 1 (p < 0.0001), 20 +/- 1, and 17 +/- 1. NPPV was well tolerated, and only two patients required sedation. Initial delivered minute ventilation was 16 +/- 4 L/min. The mean (+/- SD) peak inspiratory pressure to ventilate in the NPPV-treated patients was 18 +/- 5 cm H2O and always less than 25 cm H2O. There was no complication or problem with expectorating of secretions. Oral intake (liquid diet) was preserved. Two patients required intubation (35 min and 89 h into NPPV) for worsening PaCO2. Duration of NPPV was 16 +/- 21 h. All patients survived. Length of hospital stay was 5 +/- 4 days.
In asthmatic patients with ARF, NPPV via a face mask appears highly effective in correcting gas exchange abnormalities using a low inspiratory pressure (< 25 cm H2O). A randomized study is in progress to assess fully the role of NPPV in status asthmaticus.
在患有急性呼吸衰竭(ARF)的哮喘患者中,放置气管内导管会导致高并发症发生率,并增加气道阻力。在急性哮喘中,面罩持续气道正压通气(CPAP)可降低气道阻力和呼吸功(WOB),但不能改善气体交换。在伴有ARF的慢性阻塞性肺疾病(COPD)中,在面罩CPAP基础上加用间歇正压通气可进一步改善WOB,并在纠正气体交换异常方面非常有效。在我们的医学重症监护病房(ICU),无创正压通气(NPPV)被用作符合条件的高碳酸血症性ARF患者的一线干预治疗。我们报告了我们在3年期间对17例哮喘合并ARF患者应用NPPV的经验。
用头带固定面罩,避免过紧,连接至呼吸机(PB - 7200)。初始通气设置包括4±2 cm H₂O的CPAP以抵消内源性呼气末正压,以及14±5 cm H₂O的压力支持通气(PSV),目标是呼吸频率低于25次/分钟,呼出潮气量为7 mL/kg或更多。然后根据动脉血气结果调整PSV。
平均年龄为35.4±11.3岁;10例为女性。报告了NPPV开始时、开始后不到2小时、2至6小时以及12至24小时不同生理值的平均值(±标准误)。pH值分别为7.25±0.01、7.32±0.02(p = 0.0012)、7.36±0.02(p < 0.0001)和7.38±0.02;动脉血二氧化碳分压(PaCO₂)分别为65±2、52±3(p = 0.002)、45±3(p < 0.0001)和45±4;吸入氧分数下的动脉血氧分压(PaO₂)分别为315±41、403±47、367±47和472±67(p = 0.06);呼吸频率分别为29.1±1、22±1(p < 0.0001)、20±1和17±1。NPPV耐受性良好,仅2例患者需要镇静。初始输送的分钟通气量为16±4 L/min。接受NPPV治疗患者通气时的平均(±标准差)吸气峰压为18±5 cm H₂O,且始终低于25 cm H₂O。咳痰无并发症或问题。维持口服摄入(流食)。2例患者因PaCO₂恶化需要插管(NPPV开始后35分钟和89小时)。NPPV持续时间为16±21小时。所有患者均存活。住院时间为5±4天。
在患有ARF的哮喘患者中,通过面罩进行NPPV似乎在使用低吸气压力(< 25 cm H₂O)纠正气体交换异常方面非常有效。一项随机研究正在进行中,以全面评估NPPV在哮喘持续状态中的作用。